Detalles de la búsqueda
1.
Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
Vox Sang;
119(1): 27-33, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986640
2.
Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma.
Vox Sang;
118(4): 296-300, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36734378
3.
Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
Trials;
22(1): 70, 2021 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33472681
4.
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
J Clin Invest;
131(20)2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473652
5.
A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol.
Stem Cells Int;
2018: 6025918, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29535772
Resultados
1 -
5
de 5
1
Próxima >
>>